TAGI Pharma, Inc.June 12, 2025

FDA 483 - TAGI Pharma, Inc. - June 12, 2025

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore TAGI Pharma, Inc.

Record Details

An FDA inspection of TAGI Pharma, Inc. in South Beloit, IL, revealed a significant issue regarding the timely submission of annual reports for approved drug products. The firm failed to submit these reports within 60 days of the anniversary date for multiple products, including Dexmedetomidine HCl and Methazolamide Tablets, for reporting years 2023, 2024, and 2025. This indicates a lapse in regulatory compliance concerning post-approval reporting requirements.

Company: TAGI Pharma, Inc.
Inspection Date: June 12, 2025
Product Type: Drugs
Office: Chicago District Office
Person: Jeanne J. Thai (investigator)

Open in Dashboard

ID · 340bc641-631d-4ca5-a58a-84fc43675988